Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Amar G. Chittiboyina is active.

Publication


Featured researches published by Amar G. Chittiboyina.


Hypertension | 2004

Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity

Stephen C. Benson; Harrihar A. Pershadsingh; Christopher Ho; Amar G. Chittiboyina; Prashant V. Desai; Michal Pravenec; Nianning Qi; Jiaming Wang; Mitchell A. Avery; Theodore W. Kurtz

Abstract—The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome proliferator–activated receptor-γ (PPARγ) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARγ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes. Here we report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARγ; influence the expression of PPARγ target genes involved in carbohydrate and lipid metabolism; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet. None of the other commercially available angiotensin II receptor antagonists appeared to activate PPARγ when tested at concentrations typically achieved in plasma with conventional oral dosing. In contrast to ordinary antihypertensive and antidiabetic agents, molecules that can simultaneously block the angiotensin II receptor and activate PPARγ have the potential to treat both hemodynamic and biochemical features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.


Current Medicinal Chemistry | 2008

Type 2 diabetes and oral antihyperglycemic drugs.

Mitchell A. Avery; Cassia S. Mizuno; Amar G. Chittiboyina; Theodore W. Kurtz; Harrihar A. Pershadsingh

Type II diabetes is a heterogeneous disease where environment and genetics are important factors for the expression of the disease. The high cost for treating complications of diabetes is a burden for public health systems and governments worldwide. Type II diabetes has been causing debilitation worldwide for many decades, and a single drug that safely treats the disease has yet to be discovered. Sulfonylureas, biguanides, alpha-glucosidase, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes.


Current Pharmaceutical Design | 2005

The Epothilones and Related Analogues-A Review of Their Syntheses and Anti-Cancer Activities

E. Blake Watkins; Amar G. Chittiboyina; Jae-Chul Jung; Mitchell A. Avery

The macrocylic polyketide class of compounds known as the epothilones has generated substantial interest over the last few years in the areas of chemistry, biology, and medicine due to their interesting structure and, more importantly, their activity against numerous cancer cell lines, including drug-resistant, especially Taxol-resistant, cancer cell lines. To date, numerous total syntheses have been published, hundreds of epothilone analogues have been synthesized, and detailed structure activity relationship studies have been conducted. The purpose of this review is to give a brief summary of the latest advances made concerning the epothilones. Recent total or partial syntheses will be presented along with the syntheses of new epothilone analogues and their corresponding biological data. In addition, we will look at the current state of research into an economically viable method for the biosynthesis of the epothilones and related analogues.


The FASEB Journal | 2013

Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens

Yan Jiang; Ping Gong; Zeynep Madak-Erdogan; Teresa A. Martin; Muthu Jeyakumar; Kathryn E. Carlson; Ikhlas A. Khan; Tj Smillie; Amar G. Chittiboyina; Sateesh Chandra Kumar Rotte; William G. Helferich; John A. Katzenellenbogen; Benita S. Katzenellenbogen

Because little is known about the actions of botanical estrogens (BEs), widely consumed by menopausal women, we investigated the mechanistic and cellular activities of some major BEs. We examined the interactions of genistein, daidzein, equol, and liquiritigenin with estrogen receptors ERα and ERβ, with key coregulators (SRC3 and RIP140) and chromatin binding sites, and the regulation of gene expression and proliferation in MCF‐7 breast cancer cells containing ERα and/or ERβ. Unlike the endogenous estrogen, estradiol (E2), BEs preferentially bind to ERβ, but their ERβ‐potency selectivity in gene stimulation (340‐ to 830‐fold vs. E2) is enhanced at several levels (coregulator recruitment, chromatin binding); nevertheless, at high (0.1 or 1 μM) concentrations, BEs also fully activate ERα. Because ERα drives breast cancer cell proliferation and ERβ dampens this, the relative levels of these two ERs in target cells and the BE dose greatly affect gene expression and proliferative response and will be crucial determinants of the potential benefits vs. risks of BEs. Our findings reveal key and novel mechanistic differences in the estrogenic activities of BEs vs. E2, with BEs displaying patterns of activity distinctly different from those seen with E2 and provide valuable information to inform future studies.—Jiang, Y., Gong, P., Madak‐Erdogan, Z., Martin, T., Jeyakumar, M., Carlson, K., Khan, I., Smillie, T. J., Chittiboyina, A. G., Rotte, S. C. K., Helferich, W. G., Katzenellenbogen, J. A., Katzenellenbogen, B. S. Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J. 27, 4406–4418 (2013). www.fasebj.org


Journal of Biological Chemistry | 2013

Functional identification of valerena-1,10-diene synthase, a terpene synthase catalyzing a unique chemical cascade in the biosynthesis of biologically active sesquiterpenes in Valeriana officinalis

Yun Soo Yeo; S. Eric Nybo; Amar G. Chittiboyina; A Weerasooriya; Yh Wang; Elsa Góngora-Castillo; Brieanne Vaillancourt; C. Robin Buell; Dean DellaPenna; Mary Dawn Celiz; A. Daniel Jones; Eve Syrkin Wurtele; Nick Ransom; Natalia Dudareva; Khaled A. Shaaban; Nidhi Tibrewal; Suman Chandra; Tj Smillie; Ikhlas A. Khan; Robert M. Coates; David S. Watt; Joseph Chappell

Background: Therapeutic values of Valeriana officinalis have been associated with sesquiterpenes whose biosynthetic origins have remained enigmatic. Results: A cyclobutenyl intermediate in the catalytic cascade of valerena-1,10-diene synthase is reported. Conclusion: A new class of sesquiterpene synthases for the biosynthesis of sesquiterpenes harboring isobutenyl functional groups is proposed. Significance: Similar catalytic mechanisms from evolutionarily diverse organisms are proposed and portend sources for sesquiterpene diversity. Valerian is an herbal preparation from the roots of Valeriana officinalis used as an anxiolytic and sedative and in the treatment of insomnia. The biological activities of valerian are attributed to valerenic acid and its putative biosynthetic precursor valerenadiene, sesquiterpenes, found in V. officinalis roots. These sesquiterpenes retain an isobutenyl side chain whose origin has been long recognized as enigmatic because a chemical rationalization for their biosynthesis has not been obvious. Using recently developed metabolomic and transcriptomic resources, we identified seven V. officinalis terpene synthase genes (VoTPSs), two that were functionally characterized as monoterpene synthases and three that preferred farnesyl diphosphate, the substrate for sesquiterpene synthases. The reaction products for two of the sesquiterpene synthases exhibiting root-specific expression were characterized by a combination of GC-MS and NMR in comparison to the terpenes accumulating in planta. VoTPS7 encodes for a synthase that biosynthesizes predominately germacrene C, whereas VoTPS1 catalyzes the conversion of farnesyl diphosphate to valerena-1,10-diene. Using a yeast expression system, specific labeled [13C]acetate, and NMR, we investigated the catalytic mechanism for VoTPS1 and provide evidence for the involvement of a caryophyllenyl carbocation, a cyclobutyl intermediate, in the biosynthesis of valerena-1,10-diene. We suggest a similar mechanism for the biosynthesis of several other biologically related isobutenyl-containing sesquiterpenes.


Journal of Agricultural and Food Chemistry | 2013

Bioactivity-Guided Investigation of Geranium Essential Oils as Natural Tick Repellents

Nurhayat Tabanca; Mei Wang; Cristina Avonto; Amar G. Chittiboyina; Jon F. Parcher; John F. Carroll; Matthew Kramer; Ikhlas A. Khan

The evaluation of 10 essential oils of geranium, Pelargonium graveolens (Geraniaceae), were all shown to have repellent activity against nymphs of the medically important lone star tick, Amblyomma americanum (L.). The biological tests were carried out using a vertical filter paper bioassay, where ticks must cross an area of the paper treated with repellent to approach host stimuli. One of the essential oil samples that repelled >90% of the ticks at 0.103 mg/cm(2) was selected for further fractionation studies. The sesquiterpene alcohol, (-)-10-epi-γ-eudesmol, was isolated and identified by spectral methods. (-)-10-epi-γ-Eudesmol at 0.103 and 0.052 mg of compound/cm(2) of filter paper repelled 90 and 73.3% of the ticks, respectively. (-)-10-epi-γ-Eudesmol exhibited similar repellency to the reference standard N,N-diethyl-meta-toluamide (DEET) at concentrations of ≥0.052 mg of compound/cm(2) of filter paper, with (-)-10-epi-γ-eudesmol losing much of its repellency at 0.026 mg of compound/cm(2) and DEET at 0.013 mg of compound/cm(2). Isomenthone and linalool did not repel ticks at the concentrations tested. Most repellents are marketed with much higher concentrations of active ingredient than the concentrations of the natural repellents tested herein; therefore, effective compounds, such as (-)-10-epi-γ-eudesmol, found in geranium oil, have the potential for commercial development.


Journal of Medicinal Chemistry | 2010

Design, Synthesis, and Development of Novel Guaianolide-Endoperoxides as Potential Antimalarial Agents

Lingzhi Sun; Falgun Shah; Mohamed A. Helal; Yunshan Wu; Yakambram Pedduri; Amar G. Chittiboyina; Jiri Gut; Philip J. Rosenthal; Mitchell A. Avery

Design and synthesis of a guaianolide-endoperoxide (thaperoxide) 3 was pursued as a new antimalarial lead which was found to be noncytotoxic as compared to the natural product lead thapsigargin 2. Several analogues of 3 were successfully synthesized and found to be comparable to derivatives of artemisinin 1 in in vitro antimalarial assay. Among the synthesized compounds, 22 showed excellent in vitro potency against the cultured parasites (W2 IC(50) = 13 nM) without apparent cytotoxicity. Furthermore, SAR trends in thaperoxide analogues are presented and explained with the help of docking studies in the homology model of PfSERCA(PfATP6).


Journal of Medicinal Chemistry | 2010

Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome

Cassia S. Mizuno; Amar G. Chittiboyina; Falgun Shah; Akshay Patny; Theodore W. Kurtz; Harrihar A. Pershadsingh; Robert C. Speth; Vardan T. Karamyan; Paulo Carvalho; Mitchell A. Avery

In addition to lowering blood pressure, telmisartan, an angiotensin (AT(1)) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT(1) receptor with a K(i) = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPARgamma activity (29%) and affinity for the AT(1) receptor (K(i) = 2.5 microM).


Journal of Natural Products | 2015

Cytotoxic activity of rearranged drimane meroterpenoids against colon cancer cells via down-regulation of β-catenin expression.

In Hyun Hwang; Joonseok Oh; Wei Zhou; Seoyoung Park; Joo Hyun Kim; Amar G. Chittiboyina; Daneel Ferreira; Gyu Yong Song; Sangtaek Oh; MinKyun Na; Mark T. Hamann

Colorectal cancer has emerged as a major cause of death in Western countries. Down-regulation of β-catenin expression has been considered a promising approach for cytotoxic drug formulation. Eight 4,9-friedodrimane-type sesquiterpenoids (1–8) were acquired using the oxidative potential of Verongula rigida on bioactive metabolites from two Smenospongia sponges. Compounds 3 and 4 contain a 2,2-dimethylbenzo[d]oxazol-6(2H)-one moiety as their substituted heterocyclic residues, which is unprecedented in such types of meroterpenoids. Gauge-invariant atomic orbital NMR chemical shift calculations were employed to investigate stereochemical details with support of the application of advanced statistics such as CP3 and DP4. Compounds 2 and 8 and the mixture of 3 and 4 suppressed β-catenin response transcription (CRT) via degrading β-catenin and exhibited cytotoxic activity on colon cancer cells, implying that their anti-CRT potential is, at least in part, one of their underlying antineoplastic mechanisms.


Biochimica et Biophysica Acta | 2014

The first cyclomegastigmane rhododendroside A from Rhododendron brachycarpum alleviates HMGB1-induced sepsis.

Wei Zhou; Joonseok Oh; Wonhwa Lee; Soyoung Kwak; Wei Li; Amar G. Chittiboyina; Daneel Ferreira; Mark T. Hamann; Seung Ho Lee; Jong-Sup Bae; MinKyun Na

BACKGROUND Endangered plant species are a vital resource for exploring novel drug prototypes. A Korean endangered plant Rhododendron brachycarpum G. Don is a broad-leaved shrub native to northern Korea and central Japan. The high mobility group box 1 protein (HMGB1) could be a specific target for the discovery of novel antiseptic agents. METHODS Gauge-invariant atomic orbital (GIAO) NMR chemical shift calculations were applied for investigation of stereochemical details with accuracy improved by application of DP4 analysis. In vitro antiseptic mechanisms were investigated utilizing immunofluorescence staining, ELISA and cell-cell adhesion assay. Cecal ligation and puncture (CLP) operation was employed to evaluate in vivo potential alleviating severe sepsis and septic shock. RESULTS The first bicyclic megastigmane glucoside rhododendroside A (1) along with known megastigmane glucosides (2-5) were isolated from the leaves of R. brachycarpum. The structure of 1 was established by NMR analysis as well as comparison of the experimental chemical shifts with those of computed values employing DP4 application. In the CLP operation model that simulates severe sepsis, rhododendroside A (1) improved the survival rate up to 60%. CONCLUSIONS Our results exhibit that R. brachycarpum may produce a unique scaffold that is developed into a drug lead mitigating HMGB1-induced vascular pro-inflammatory stimuli and thus alleviating severe sepsis and related manifestations. GENERAL SIGNIFICANCE Discovery of new drug leads would warrant conservation efforts of endangered species.

Collaboration


Dive into the Amar G. Chittiboyina's collaboration.

Top Co-Authors

Avatar

Ikhlas A. Khan

University of Mississippi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bharathi Avula

University of Mississippi

View shared research outputs
Top Co-Authors

Avatar

Mei Wang

University of Mississippi

View shared research outputs
Top Co-Authors

Avatar

Jianping Zhao

University of Mississippi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yh Wang

Taipei Veterans General Hospital

View shared research outputs
Top Co-Authors

Avatar

Mingkui Wang

Huazhong University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yan-Hong Wang

University of Mississippi

View shared research outputs
Researchain Logo
Decentralizing Knowledge